“Global Dengue Vaccine Market Outlook 2024: Global Opportunity And Demand Analysis, Market Forecast, 2018-2024” presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and deal landscapes.
Top Leading Companies: Sanofi Pasteur, Biological E. Limited, Merck & Co., Glaxosmithkline, Pfizer, Panacea Biotech Ltd., Vabiotech, Butantan Institute.
Request a Sample Copy at: https://www.industrydataanalytics.com/request-sample-page.php?gturl=19364?source=mednewsledger&Mode=07
Essential points covered in Global Dengue Vaccine Market 2018 Research are:-
- What will the market size and the growth rate be in 2024?
- What are the key factors driving the Global Dengue Vaccine market?
- What are the key market trends impacting the growth of the Global Dengue Vaccine market?
- What are the challenges to market growth?
- Who are the key vendors in the Global Dengue Vaccine market?
- What are the market opportunities and threats faced by the vendors in the Global Dengue Vaccine market?
- What are the key outcomes of the five forces analysis of the Global Dengue Vaccine market?
This independent 280 pages report guarantees you will remain better informed than your competition. With over 100 tables and figures examining the Dengue Vaccine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2024.
o Live attenuated vaccine
o Chimeric Live attenuated vaccine
o Subunit vaccine
o Inactivated vaccine
o Nucleic acid based vaccine
By End Users
o Diagnostic Labs
o Government Institutes
o Others (retail pharmacies, online pharmacies, etc)
Geographically, this report is segmented into several key Regions, with Sales, revenue, Market Share (%) and Growth Rate (%) of Automotive Tubeless Tires in these regions 2016 to 2024 (forecast), covering North America , Latin America , Europe , Asia-Pacific , Middle East and Africa (MEA) , Rest of World.
Dengvaxia (CYD-TDV), first dengue vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule invented by Sanofi Pasteur. CYD-TDV and DENVax are expected to lose market share to the domestically-produced live-attenuated vaccine, TV-003 due to its lower price. Today dengue resides in 125 countries around the world and Aedes aegypti, the primary vector is everywhere, making transmission reduction is the major area of concern.
According to WHO, number of deaths caused by dengue virus was 297, 873 in 2012 and 159 per million in low income, lower-middle income and upper-middle income regions. The global market for dengue vaccines holds the opportunities for drugmakers when the will be able to successfully develop effective vaccines for all age group. The major growth driver of global dengue vaccine market is the process of urbanization.
Merger & acquisition is the key strategy for the vendors of dengue market, for instance, Sanofi “Be a Wall against Dengue” disease education campaign to raise awareness on dengue prevention in Singapore, launched under partnership of Pasteur and Ya Kun Kaya Toast in conjunction with ASEAN Dengue Day (15 June 2017). Similarly, Takeda pharmaceutical company and Biological E. limited entered into a partnership for the development and delivery of low-cost combination vaccines. There are 5 vaccines in Phase I-III and 4 first-in-class vaccines in pipeline assessment.
Market Size and Forecast:
Global dengue vaccine market valued USD 0.22 billion in 2016 and is expected to reach USD 1.15 by 2024 at a CAGR of 17% over the forecast period.
Government Institutes dominate the global dengue vaccine market, accounting 45% market share in 2017 and is expected to account for 52% global dengue vaccine market share by 2024 followed by hospitals, diagnostic labs and NGO’s.
Geographically, more than 70% of global dengue vaccine revenue was emanated from APAC in 2016. Countries like Brazil, Mexico, Thailand, Singapore and India are the leading market for dengue vaccine. In America, around 500 million people are at the risk of getting dengue.
Browse Full Report at: https://www.industrydataanalytics.com/global-dengue-vaccine-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024-19364-p.php?source=mednewsledger&Mode=07
Market Drivers and Challenges:
The key driving factors of global dengue market are increasing dengue fever occurrence, promising end stage vaccine pipeline, local production of dengue vaccines and innovation of live attenuated tetravalent dengue vaccine. However, less number of skilled professionals and unavailability of optimum diagnostic systems where dengue fever is visualized as a common febrile disease have driven the global dengue vaccine market.
Unplanned and uncontrolled urbanization, stiff competition among existing players, high possibilities of side effects, lack of basic amenities in communities, poor environmental management, and climatic change hinders the global dengue vaccine market. In addition, supply side infrastructure bottlenecks such as surveillance system, standardized diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the restraints responsible for the decline of global dengue vaccine market.
Industrydataanalytics provides syndicated Market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. Industrydataanalytics has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
+1 (704) 266-3234 |Mail to: email@example.com
Dr Nancy Miller has over 20 years experience as a educator and health practitioner. She has a B.S. from Lake Head University In Thunder Bay, and a Ph.D. in biology from the University of Guelph . Dr. Miller has worked as a special medical consultant for a major insurance provider before becoming a freelance health author and public speaker. There are several ways to contact Dr. Miller here.